Business
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":" STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that two abstracts and posters have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS).\n\nSABCS 2021 will be held in a hybrid in-person and virtual format from December 7-10, 2021. SABCS anticipates publishing the two posters on the evening of December 8, 2021.\n\nSnehal Patel, CEO of Greenwich LifeSciences, commented, “We are thrilled to be presenting our 4th poster of our 5 year Phase IIb data at SABCS, completing a full year of publications. This data is a result of our ongoing data analysis and will speak to the mechanism of GP2 and the potential to use immune response data in novel ways. As a result of our previously published immune response data and this upcoming data, we plan to substantially improve the immune response technology and to increase the frequency of testing and sample collection in our Phase III trial. This data will be published on the 1 year anniversary of our initial poster at SABCS showing the 100% disease free survival or 0% metastatic breast cancer recurrence rate over 5 years of follow-up.”\n\nThe second abstract and poster will present additional features of the Phase III clinical trial providing information to breast cancer clinicians who will be attending the in-person conference, visiting our poster session, and participating in our first Phase III trial investigator meeting where the global primary investigator and the Company will present the trial to participating clinicians.\n\nAbout SABCS\n\nThe 44th annual SABCS has grown to be the industry’s premier breast cancer conference for basic, translational, and clinical cancer research professionals. It is well-known for presenting the latest breast cancer data from all over the world. More than 7,500 health care professionals from more than 90 countries attend annually. For more information, please visit the conference website at: https://www.sabcs.org/\n\nAbout FLAMINGO-01 and GLSI-100\n\nThe Phase III clinical trial will be called FLAMINGO-01 and the combination of GP2 + GM-CSF will be called GLSI-100. The P...